Cardiac Magnetic Resonance Spectroscopic Correlates of Cardiac Sympathetic Denervation in Parkinson’s disease: A Comparison with MSA-P and Healthy Controls

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006061

Enrollment

Registered

2014-05-30

Start date

2012-12-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20 G90.3

Interventions

Group 1: Patients with Parkinson's Disease (questionnaires, routine tilt-table testing, routine MIBG, study MRI) Group 2: Patients with multiple system atrophy (parkinsonian variant

questionnaires, routine tilt-table testing, routine MIBG, study MRI) Group 3: Healthy controls (questionnaires, tilt-table testing, MIBG scintigraphy, MRI

all as part of the study protocol)

Eligibility

Sex/Gender

All

Age

30 Years to 90 Years

Inclusion criteria

Inclusion criteria: PD Patients: • Clinical diagnosis of PD according to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria (Hughes, Ben-Shlomo et al. 1992) • Current age between 30 – 90 years • The subject must be able to give written informed consent (full contractual capability) • The subject must be willing to participate in all study related activities and visits MSA Patients: • Clinical diagnosis of probable MSA-P according to the revised Gilman criteria (Gilman, Wenning et al. 2008) • Current age between 30 – 90 years • The subject must be able to give written informed consent (full contractual capability) • The subject must be willing to participate in all study related activities and visits Healthy volunteers: • Current age between 30 – 90 years • The subject must be able to give written informed consent (full contractual capability) • The subject must be willing to participate in all study related activities and visits

Exclusion criteria

Exclusion criteria: • History of other major neurological or psychiatric disorders or conditions • History of coronary heart disease, ischemic and non-ischemic cardiomyopathy • Heart failure determined by echocardiography (ejection fraction below reference range) • Cardiac denervation unrelated to parkinsonism (e.g. diabetic neuropathy or heart transplantation as determined by history or laboratory findings [i.e. HbA1c]) • Known or suspected pregnancy or breastfeeding • Presence of contraindication to MRI (e.g. implants) • Dependence on any drug that intereferes with MIBG

Design outcomes

Primary

Measure	Time frame
Diagnostic value of cardiac magnetic resonance spectroscopy profiles in differentiating PD, MSA and healthy controls	—

Secondary

Measure	Time frame
Correlation of imaging read-outs with cardiovascular autonomic measures	—

Countries

Austria

Contacts

Public ContactGregor Wenning

Abteilung für Neurobiologie, Department für Neurologie, Medizinische Universität Innsbruck

gregor.wenning@i-med.ac.at+435125040

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026